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performed on DNA of lung cancer cell lines and primary tumors have 
demonstrated non-random and consistent gains and losses of genetic 
materials on various chromosomal arms (23-25). Large gains indicate 
gene ampliﬁcation, some of which represent potential oncogenes. 
In contrast, genes that are commonly lost have a high probability of 
being tumor suppressor genes. One of the chromosomal arms that 
show a high frequency of genetic gains in non-small cell lung cancer 
is 5p (short arm). Zhu et al (26,27) has previously demonstrated that 
overexpression and/or high ampliﬁcation of two genes located on 5p, 
Skp2 (5p13) and hTERT (5p15) are associated with poor prognosis 
in a subgroup of NSCLC patients. Future studies will likely identify 
additional genomic copy signatures that could be strong classiﬁers for 
patients with signiﬁcantly different clinical outcomes. 
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Sleeve lobectomy for lung cancer was ﬁrst described as a compro-
mise operation for patients whose pulmonary reserve was considered 
inadequate to permit pneumonectomy. Since then, several authors have 
suggested that sleeve resection may provide as good if not better results 
than pneumonectomy in selected cases of primary lung cancer involving 
the proximal bronchial tree. Whether sleeve resection is radical enough 
and indicated for patients who could tolerate pneumonectomy contin-
ues to be debated among thoracic surgeons and indeed there are only 
a handful of reports of clinical series comparing operative mortality, 
survival, and sites of recurrences between these procedures (Table 1).
Table 1 - Comparison of survival between sleeve resection and  
pneumonectomy
Authors (yr) No pts 5 year survival (%)
Sleeve resection Pneumonectomy
Gaissert (1996) 128 42 % 44 %
Yoshino (1997) 58 66 % 59 %
Suen (1999) 200 38 % 36 %
Ludwig (2005) 310 39 % 27 %
Takeda (2006) 172 54 % 33 %
Operative mortality, survival, and sites of recurrences were compared 
in 1,346 consecutive patients who underwent pneumonectomy (N : 
1,046) or sleeve resection in our institution over a 25-year interval 
(Table 2).
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Table 2 - Sleeve lobectomy versus pneumonectomy for lung cancer
Sleeve lobectomy Pneumonectomy
No of patients 300(1976-2005) 1,046 (1980-2000)
Mean age 61.2 ± 11 years 60.7 ± 9.4 years
Operative mortality 2.7 % (8 / 300) 5.3 % (55 / 1,046)
Overall 5 year survival 54 % 31 %
Locoregional recurrences 16 % 35 %
During that period, sleeve resection was always done whenever techni-
cally possible while pneumonectomy was reserved for lesions that 
could not be removed by a bronchoplastic procedure. While lesions in 
the hilum of the right upper lobe were the commonest indication for 
sleeve resection, all lobes of either lung could be involved with tumors 
amenable to some form of lung-sparing bronchoplastic procedure. All 
patients included in the analysis were staged by nodal sampling and 
according to the 1997 revised TNM nomenclature.
There were 8 operative deaths out of 300 patients who underwent 
sleeve resection (2.7 %) and 55 operative deaths out of the 1,046 
patients who underwent pneumonectomy (5.3 %, p < 0.05) and most 
causes of death in either group were related to respiratory events. Of 
note, four patients (1.3 %) had anastomotic complications after sleeve 
resection but none of these complications lead to mortality.
Follow-up was complete for the entire cohort and the overall 5-year 
survival was signiﬁcantly better after sleeve resection (54 %) than after 
pneumonectomy (31 %, p < 0.0001) (see Table 2). For patients with 
N1 disease, there was also a signiﬁcant difference in survival favoring 
sleeve lobectomy (sleeve resection (N : 72) : 50 %; pneumonectomy 
(N : 361) : 34 %; p 0.015). When recurrences occurred, the site of ﬁrst 
recurrence was locoregional in 16 % after sleeve resection and in 35 % 
of patients after pneumonectomy.
In summary, this analysis demonstrates that sleeve resection is an effec-
tive procedure for patients who could tolerate a pneumonectomy but in 
whom the surgeon judges that a complete resection is possible through 
a bronchoplastic procedure with conservation of pulmonary function. 
As a general statement, sleeve lobectomy should be considered in any 
case of lung cancer which can be completely resected by this technique.
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The indication for a sleeve resection for lung cancer is well established: 
a tumor arising at the origin of a lobar bronchus but not inﬁltrating as 
far as to require pneumonectomy. In addition, a sleeve resection may 
be indicated when N1 nodes inﬁltrate the bronchus from the outside, 
as is often the case in the left upper lobe tumors requiring a combined 
reconstruction of the bronchus and the pulmonary artery. From a func-
tional point of view, sleeve lobectomy is strictly indicated in patients 
who cannot withstand pneumonectomy, but recent experiences have 
shown that the advantages of sparing lung parenchyma are evident also 
in patients without cardio-pulmonary impairment. Oncologically, the 
primary goal is in every case the complete resection of the tumor with 
free resection margins. 
When analyzing survival data reported in literature in the last 15 years, 
most of the studies show similar or better results for parenchymal 
sparing resections if compared with pneumonectomy. Moreover, in the 
analysis of 5-year survival according to stage (Table-1) and nodal sta-
tus, sleeve lobectomy results in higher survival rates for stages I, II and 
III, although the survival advantage in stage III appears to be limited. In 
a recent report (Ludwig’05), sleeve lobectomy results a statistically sig-
niﬁcant favourable prognostic factor for long-term survival with a sur-
vival advantage in patients with N0, N1 and N2 disease. However, this 
prognostic advantage for stage III-N2 patients is not always conﬁrmed, 
and there are other studies reporting a more evident adverse effect on 
survival for patients with N2 involvement who have undergone sleeve 
lobectomy. Therefore the role of parenchymal sparing operations in pa-
tients with N2 disease still remains not completely deﬁned (Fadel’02).
Table 1
Author (year) Stage I patients
Stage II 
patients
Stage III 
patients
Stage I  
5-yr 
survival 
(%)
Stage II 
5-yr 
survival 
(%)
Stage III  
5-yr  
survival 
(%)
Sleeve Lobectomy
Van Schil (‘91) 61 57 - 59 21 -
Gaissert (‘96) 29 31 12 42 53 43
Icard (‘99) 32 57 16 60 30 27
Tronc (‘00) 83 73 26 63 48 8
Fadel (‘02) 54 47 36 55 62 21
Mezzetti (‘02) 34 32 17 61 39 9
Terzi (‘02) 48 52 50 60 32 22
Deslauriers (‘04) 83 72 29 66 50 19
Kim (‘05) 14 18 15 88 52 8
Ludwig (‘05) 31 41 44 57 40 22
Pneumonectomy
Gaissert (‘96) 9 25 21 - 43 -
Mizushima (‘97) 8 15 84 58 42 13
Deslauririers (‘04) 164 361 471 50 34 22
Kim (‘05) 28 11 10 75 36 38
Ludwig (‘05) 31 52 111 45 42 13
These results justify the increasing use of parenchymal sparing proce-
dures for lung cancer also in patients with good cardio-pulmonary func-
tion, as observed in the last years. 
Postoperative morbidity and mortality data reveal overall better results 
for patients undergoing sleeve lobectomy with respect to pneumonec-
tomy (Table-2). Looking at literature data, when morbidity is evaluated 
according to the type of complication, pneumonectomy patients appear 
to experience a higher rate of cardiac complications, while sleeve lo-
bectomy patients show increased pulmonary and airway complications 
incidence.
The incidence of microscopic inﬁltration of the bronchial margins has 
strong signiﬁcance when analyzing the anastomotic complication and 
local recurrence rate. Authors (Kim’05) who have observed a signiﬁ-
cantly higher incidence of anastomotic leak in their sleeve lobectomy 
series, report an increased rate of positive margins on frozen section. In 
our experience (since 1989) of 192 bronchial sleeve resections and 100 
